Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 Biomarker disease BEFREE 1%) with normal concentrations of 17-OHP after stimulation were found to be carriers of CYP21 gene mutations, indicating low positive predictive values of ACTH stimulation as a screening test for carriers of 21-hydroxylase deficiency. 10427156 1999
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 AlteredExpression disease BEFREE A standard dose adrenocorticotropic hormone (ACTH) test revealed an inadequate cortisol response and high 17-hydroxy progesterone levels, suggesting simple virilising congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. 30074481 2019
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 AlteredExpression disease BEFREE After ACTH testing, 13 out of the 32 (41%) cases displayed higher 17-hydroxyprogesterone (17-OHP) levels than normal but less than those found in patients affected by nonclassical adrenal hyperplasia (CAH); these levels were similar to those observed in obligate heterozygotes for CAH due to 21-hydroxylase deficiency (21-OHD). 9666866 1998
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 Biomarker disease BEFREE Although 12 % of patients with adrenal incidentalomas had an exaggerated response of 17 OHP after ACTH administration indicating a possible 21-hydroxylase deficiency, these findings are not associated with CYP21 mutation estimated in peripheral blood samples. 18589890 2008
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 Biomarker disease BEFREE An exaggerated response of 17- hydroxyprogesterone (17-OHP) to exogenous ACTH stimulation has been found in 30 to 70% of patients with incidentally discovered adrenal tumors, supporting the concept that congenital 21- hydroxylase deficiency may be a predisposing factor for adrenocortical tumorigenesis. 17848847 2007
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 Biomarker disease BEFREE Basal and ACTH-stimulated hormonal results revealed non-classical 21-hydroxylase deficiency-like status in one patient (3.6%), and 21-hydroxylase deficiency heterozygote carrier-like state in four patients (14.3%), while the other 23 patients (82.1%) had functional adrenal hyperandrogenism (FAH). 14513878 2003
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 Biomarker disease BEFREE Basal blood levels of steroid hormones and serum levels of 17-hydroxyprogesterone at 1 h after intravenous injection of adrenocorticotropic hormone demonstrated that 21-hydroxylase deficiency was not the underlying cause of her virilization. 28190856 2017
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 Biomarker disease BEFREE Based on published nomogram standards for serum 17-hydroxyprogesterone (17-OHP), seven patients (30%) were diagnosed as having the nonclassical symptomatic form of 21-hydroxylase deficiency [mean post ACTH 4244 +/- 1113 (SD) ng/dl]. 3029158 1987
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 Biomarker disease BEFREE Detection of heterozygotes for congenital adrenal hyperplasia: 21-hydroxylase deficiency-a comparison of HLA typing and 17-OH progesterone response to ACTH infusion. 6253614 1980
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 Biomarker disease BEFREE Genotyping more patients with nonclassical 21-hydroxylase deficiency will help to redefine the cut-off value for ACTH-stimulated 17OH-P for correct diagnosis of this disease. 10792340 2000
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 Biomarker disease BEFREE Heterozygotes of late-onset 21-hydroxylase deficiency had mildly elevated 17-hydroxy-progesterone responses to ACTH. 6290362 1982
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 GeneticVariation disease BEFREE HLA typing and ACTH testing of her parents and siblings provided evidence of a linkage between HLA and 21-hydroxylase deficiency loci. 6251108 1980
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 Biomarker disease BEFREE Impaired mineralocorticoid hormone responses to adrenocorticotropin stimulation: additional characterization of heterozygosity for the 21-hydroxylase deficiency type of congenital adrenal hyperplasia. 6311859 1983
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 Biomarker disease BEFREE In all patients, hormonal evaluation for 21-hydroxylase deficiency was performed using measurements of basal and ACTH-stimulated plasma 17-hydroxyprogesterone (17-OHP) concentrations. 12213672 2002
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 Biomarker disease BEFREE In all the members of this family who were tested, the response of 17-hydroxyprogesterone and progesterone to adrenocorticotropic hormone stimulation was either normal or of the type seen in heterozygotes for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. 3808511 1987
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 AlteredExpression disease BEFREE Lack of ACTH and androgen receptor expression in a giant adrenal myelolipoma associated with 21-hydroxylase deficiency. 18618087 2008
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 AlteredExpression disease BEFREE Mutant P450c21 enzymes carrying specific amino acid substitutions seen in patients with 21-hydroxylase deficiency exhibit activities that correlate with the clinical severity of the disease and with biochemical abnormalities such as 17-hydroxyprogesterone levels after ACTH (corticotropin) stimulation. 1958556 1991
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 Biomarker disease BEFREE NCAH due to 21-hydroxylase deficiency is diagnosed when the ACTH-stimulated 17-OHP levels > 30 nmol/ l; this threshold varies depending on the assay. 17551465 2006
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 GeneticVariation disease BEFREE Non-classical 21-hydroxylase deficiency in children: association of adrenocorticotropic hormone-stimulated 17-hydroxyprogesterone with the risk of compound heterozygosity with severe mutations. 12222711 2002
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 Biomarker disease BEFREE Plasma 21-deoxycortisol (21-DOF) and 17-hydroxyprogesterone (17-OHP) concentrations were assayed before (basal) and 1 h after ACTH stimulation in 4 groups of normal subjects (35 follicular phase women, 22 luteal phase women, 33 adult men, and 15 prepubertal children) and in a group of 31 patients with the late-onset form of congenital adrenal hyperplasia (LOCAH) due to 21-hydroxylase deficiency as well as in 31 LOCAH) heterozygotes. 2831244 1988
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 GeneticVariation disease BEFREE Screening heterozygotes for 21-hydroxylase deficiency among hirsute women: lack of utility of the adrenocorticotropin hormone test. 2840308 1988
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 AlteredExpression disease BEFREE Seven study patients and 8 controls subsequently underwent ACTH stimulation test, and none had levels compatible with a diagnosis of NC-21OHD. 19200987 2010
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 AlteredExpression disease BEFREE The 17-OH progesterone levels are elevated, as in 21-hydroxylase deficiency, while androgen levels are low; cortisol may be normal but is poorly responsive to adrenocorticotropic hormone. 18259105 2008
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 GeneticVariation disease BEFREE The 60-minute ACTH stimulation test can provide clinicians with hormonal criteria for the assessment of the genotype of classic 21-hydroxylase deficiency in the Chinese population. 7613227 1995
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
0.100 AlteredExpression disease BEFREE The aim of this study was to determine whether ACTH-stimulated 17OHP levels in obligate carriers for 21OHD would be correlated with the impairment of the enzyme activity caused by these mutations, which would affect the 17OHP cutoff level for the diagnosis of the NC form. 11836321 2002